期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1β expression 被引量:9
1
作者 Han Saem Son Jiae Lee +10 位作者 Hye In Lee Narae Kim You-Jin Jo Gong-Rak Lee seong-eun hong Minjeong Kwon Nam Young Kim Hyun Jin Kim Jin Ha Park Soo Young Lee Woojin Jeong 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2020年第3期462-474,共13页
Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity,which is closely associated with inflammation.Benzydamine(BA)has been used as a cytokine-suppressive or non-steroidal... Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity,which is closely associated with inflammation.Benzydamine(BA)has been used as a cytokine-suppressive or non-steroidal anti-inflammatory drug that inhibits the production of proinflammatory cytokines or prostaglandins.However,its role in osteoclast differentiation and function remains unknown.Here,we explored the role of BA in regulating osteoclast differentiation and elucidated the underlying mechanism.BA inhibited osteoclast differentiation and strongly suppressed interleukin-1β(IL-1β)production.BA inhibited osteoclast formation and bone resorption when added to bone marrowderived macrophages and differentiated osteoclasts,and the inhibitory effect was reversed by IL-1βtreatment.The reporter assay and the inhibitor study of IL-1βtranscription suggested that BA inhibited nuclear factor-κB and activator protein-1 by regulating IκB kinase,extracellular signal regulated kinase and P38,resulting in the down-regulation of IL-1βexpression.BA also promoted osteoblast differentiation.Furthermore,BA protected lipopolysaccharide-and ovariectomy-induced bone loss in mice,suggesting therapeutic potential against inflammation-induced bone diseases and postmenopausal osteoporosis. 展开更多
关键词 Benzydamine OSTEOCLAST Bone INTERLEUKIN-1Β Nuclear factor-κB ACTIVATOR protein-1
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部